April 2022
Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage of its Evolution
"New team focused on expanding its GPCR-focused structure-based drug design platform and enhancing translational medicine capabilities
• ‘Venture-like’ capital allocation approach to focus pipeline development through to Phase 1b/2a clinical proof of concept in patients, and optimize value generation
• Mid-term global expansion plans include drug discovery technology investments, licensing late-stage products for Japan, and strategic acquisitions
• Mr. Chris Cargill appointed as President and Chief Executive Officer
• Dr. Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D
Tokyo, Japan and Cambridge, UK, 24 March 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) today confirms that a series of Executive Management changes have been approved at the Company’s 32nd Shareholders’ Meeting today and are effective immediately (see biographies at the end)."